InspireMD Inc (OQ:NSPR)

Business Focus: Medical Equipment, Supplies & Distribution

Mar 26, 2024 07:00 am ET
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime...
Mar 06, 2024 07:00 am ET
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and operating results for the fourth quarter and...
Feb 28, 2024 07:00 am ET
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2023 financial...
Feb 12, 2024 07:00 am ET
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that the Company has appointed principal investigators (PIs) for its upcoming C-GUARDIANS II...
Jan 31, 2024 07:00 am ET
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that it has received CE Mark recertification under the European Union’s new Medical Device...
Jan 03, 2024 07:00 am ET
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of...
Dec 20, 2023 07:00 am ET
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System
InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the issuance of U.S. Patent No. 11,844,893, titled, “Shunts with Blood Flow Indicators.” The patent covers key...
Nov 27, 2023 07:00 am ET
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the company has entered into a strategic agreement with the Jacobs Institute at the State University...
Nov 06, 2023 07:00 am ET
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke today announced financial results and business updates for the third quarter ended...
Nov 02, 2023 08:00 am ET
InspireMD to Participate in Upcoming November Investor Conferences
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Officer, will participate in...
Nov 01, 2023 02:19 pm ET
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today presented 30-day results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial at the...
Oct 30, 2023 09:21 am ET
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2023 financial results on Monday,...
Oct 12, 2023 07:00 am ET
InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced its support for the Centers for Medicare and Medicaid Services (CMS) final National Coverage Determination...
Oct 03, 2023 07:00 am ET
InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced senior leadership additions and changes intended to support the company’s commercial growth initiatives,...
Aug 31, 2023 08:00 am ET
InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract detailing upcoming 30-day results from its C-Guardians U.S. IDE clinical trial has been...
Aug 08, 2023 07:00 am ET
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke today announced financial and operating results for the second quarter ended June 30,...
Jul 25, 2023 08:00 am ET
InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2023 financial results on...
Jun 26, 2023 08:00 am ET
InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it completed enrollment of its ongoing C-Guardians U.S. Investigational Device Exemption (IDE)...
May 18, 2023 08:00 am ET
InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that, in connection with the appointment of Shane Gleason as General Manager of North America and VP of...
May 16, 2023 07:00 am ET
InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease (CAD) and prevention of stroke today announced financial and operating results for the first quarter ended March 31,...
May 15, 2023 08:00 am ET
InspireMD Announces Private Placement of Up to $113.6 Million
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the Company has signed a securities purchase agreement with certain healthcare-focused institutional...
May 12, 2023 04:05 pm ET
InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host its conference call and webcast to review...
May 05, 2023 08:00 am ET
InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will now report first quarter 2023 financial results on...
May 01, 2023 08:00 am ET
InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the first carotid artery disease patient has been treated utilizing CGuard Prime, the company’s next...
Apr 27, 2023 08:00 am ET
InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2023 financial results on Tuesday,...
Mar 30, 2023 07:00 am ET
InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease (CAD) and prevention of stroke today announced financial and operating results for the fourth quarter ended December...
Mar 20, 2023 08:00 am ET
InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has promoted Andrea Tommasoli to Chief Operating Officer. Mr. Tommasoli formerly served as the...
Mar 02, 2023 08:00 am ET
InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2022 financial...
Feb 14, 2023 08:00 am ET
InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has hired medical device commercial veteran Shane Gleason as General Manager of North America and...
Nov 28, 2022 08:00 am ET
InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced a video series, “12 Days of Carotid Stenting,” which will feature leading multidisciplinary vascular...
Nov 15, 2022 04:05 pm ET
InspireMD Announces Multiple Presentations Featuring CGuard EPS and its Novel MicroNet Mesh Covering at the 2022 VEITH Symposium
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver multiple presentations at the 2022 VEITH Symposium, which is being held November 15...
Nov 08, 2022 07:00 am ET
InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease (CAD) and prevention of stroke today announced financial and operating results for the third quarter ended September...
Oct 25, 2022 08:00 am ET
InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2022 financial results on Tuesday,...
Sep 13, 2022 04:05 pm ET
InspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver a presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT)...
Sep 08, 2022 09:00 am ET
NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development
NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and In
Aug 09, 2022 07:00 am ET
InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke today announced financial and operating results for the second quarter ended June 30, 2022....
Aug 02, 2022 08:00 am ET
InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2022 financial results on...
Jul 14, 2022 08:00 am ET
InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced the appointment of endovascular pioneer Dr. Juan Parodi as a strategic advisor to the Company. Marvin Slosman,...
Jun 09, 2022 08:00 am ET
InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today provided the following highlights from multiple presentations and live case transmission, all featuring its CGuard™ Embolic...
Jun 02, 2022 08:00 am ET
InspireMD’s CGuard™ Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmission at LINC 2022
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will participate in the Leipzig Interventional Course (LINC) 2022, which is being held June 6-9...
May 10, 2022 07:30 am ET
InspireMD Reports First Quarter 2022 Financial Results and Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2022....
Apr 28, 2022 07:30 am ET
InspireMD to Report First Quarter 2022 Financial Results on May 10, 2022 and Provide Corporate Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2022 financial results on Tuesday,...
Mar 16, 2022 04:05 pm ET
InspireMD to Host Key Opinion Leader Event on Carotid Artery Disease Management and Stroke Prevention in combination with the CGuard™ Stent Platform & MicroNet™ Portfolio
InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host a Key Opinion Leader (KOL) webinar...
Mar 08, 2022 07:30 am ET
InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease, today announced financial and operating results for the fourth quarter and year...
Feb 28, 2022 07:00 am ET
InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application
InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, today announced its CGuard Carotid Stent, utilizing its proprietary...
Feb 22, 2022 04:30 pm ET
InspireMD to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 and Provide Corporate Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report fourth quarter and full year 2021...
Feb 15, 2022 08:00 am ET
InspireMD Announces Adnan Siddiqui, MD, PhD as a Member of its Scientific Advisory Board and Strategic Advisor
InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced the appointment of Adnan Siddiqui, MD, PhD,...
Jan 27, 2022 08:00 am ET
InspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS)
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease (CAD), today announced that Marvin Slosman, Chief Executive Officer, is scheduled to present at...
Jan 18, 2022 08:11 am ET
InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease (CAD), today announced that a live case demonstration featuring CGuard™ EPS will be broadcasted...
Nov 09, 2021 07:30 am ET
InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results as of and for the third...
Nov 03, 2021 04:05 pm ET
InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced that results from the investigator-initiated SIBERIA...
Oct 26, 2021 08:30 am ET
InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report third quarter 2021 financial results on...
Oct 13, 2021 08:30 am ET
InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health
InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS stent system has received a...
Aug 10, 2021 07:00 am ET
InspireMD Announces Strong Second Quarter 2021 Financial Results
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results as of and for the second...
Aug 04, 2021 08:30 am ET
InspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate Update
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report fiscal first quarter 2021 financial...
Jul 23, 2021 08:30 am ET
InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces the initiation of enrollment and successful completion of...
Jun 02, 2021 08:04 am ET
InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will present a corporate...
May 27, 2021 08:00 am ET
InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Company’s warrants, NSPR.WS and NSPR.WSB, currently...
May 21, 2021 08:30 am ET
InspireMD Commences Trading on Nasdaq-CM
InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), today announced that the Company’s shares will commence trading on The Nasdaq Capital...
May 14, 2021 06:00 am ET
InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021
InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor...
May 12, 2021 06:00 am ET
InspireMD Announces Appointment of Katie Arnold to Board of Directors
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced it has appointed seasoned marketing executive...
May 11, 2021 06:00 am ET
InspireMD Announces First Quarter 2021 Financial Results
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the first...
May 10, 2021 04:05 pm ET
InspireMD Announces Stock Exchange Listing Transfer to Nasdaq
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Company’s shares have been approved for...
May 06, 2021 06:00 am ET
InspireMD to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021
InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Benzinga...
May 04, 2021 04:15 pm ET
InspireMD to Report First Quarter 2021 Financial Results on Tuesday, May 11, 2021 and Provide Corporate Update
InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the “Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal first...
Apr 29, 2021 06:00 am ET
InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory Board
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announces the formation of its Scientific Advisory Board with its newly...
Apr 19, 2021 06:00 am ET
InspireMD Provides Corporate Update for Shareholders
InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today provided an update of recent corporate...
Apr 14, 2021 04:05 pm ET
InspireMD Announces 1-for-15 Reverse Stock Split
InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced a 1-for-15 reverse split of its...
Mar 22, 2021 07:53 am ET
InspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company’s Plans to List its Common Stock on Nasdaq at the Upcoming Special Meeting of Stockholders
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today issues a message to stockholders from InspireMD CEO, Marvin Slosman regarding...
Mar 09, 2021 06:30 am ET
InspireMD Announces Fourth Quarter and Year-End 2020 Financial Results
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the fourth...
Mar 02, 2021 06:00 am ET
InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate Update
InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the “Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal fourth...
Feb 24, 2021 06:00 am ET
InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract...
Feb 09, 2021 06:00 am ET
InspireMD Appoints Leading Interventional Cardiologist Chris Metzger, M.D. as Principal Investigator for CGuard Registration Trial in the United States
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today the appointment of Chris Metzger, M.D., system chair of clinical research...
Feb 08, 2021 04:05 pm ET
InspireMD Announces Closing of an Upsized $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the...
Feb 08, 2021 09:45 am ET
Thinking about buying stock in InspireMD, iBio, Nokia, Novan, or T2 Biosystems?
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NSPR, IBIO, NOK, NOVN, and TTOO.
Feb 04, 2021 08:30 am ET
InspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering
InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the...
Feb 03, 2021 08:32 am ET
InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announced a transaction intended to achieve distribution of CGuard EPS in...
Jan 26, 2021 06:30 am ET
InspireMD’s CGuard™ Featured in Multiple Presentations, Including a Live Case Demonstration During the Leipzig Interventional Congress January 25-29, 2021
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, announced today multiple presentations regarding CGuard EPS, including a live...
Jan 11, 2021 08:31 am ET
Thinking about buying stock in Polarityte, Moleculin Biotech, InspireMD, US Well Services, or Resonant?
NEW YORK, Jan. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTE, MBRX, NSPR, USWS, and RESN.
Nov 09, 2020 06:30 am ET
InspireMD Announces Third Quarter 2020 Financial Results
InspireMD, Inc. (NYSE American: NSPR)(“Inspire” or the “Company”), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and...
Nov 03, 2020 06:30 am ET
InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)
InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the appointment of Andrea Tommasoli as senior vice...
Nov 02, 2020 06:30 am ET
InspireMD to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020 and Provide Corporate Update
InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the “Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal third...
Oct 13, 2020 06:30 am ET
InspireMD Announces Renowned Interventional Cardiologist Gary S. Roubin, M.D., Ph.D., to Join Board of Directors
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the addition of Gary Roubin, M.D., Ph.D., to InspireMD’s Board...
Oct 06, 2020 06:30 am ET
InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide §711(a)
InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the appointment of Patrick Jamnik as vice...
Sep 10, 2020 06:30 am ET
InspireMD Announces Christina Brennan, M.D., MBA to Serve in Advisory Role for Pivotal Study of CGuard Carotid Stent System
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the addition of Dr. Christina Brennan as a strategic advisor to...
Sep 08, 2020 06:30 am ET
InspireMD Announces Approval of Investigational Device Exemption (IDE) for Pivotal Study of CGuard Carotid Stent System
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the U.S. Food and Drug Administration (“FDA” or “the Agency”)...
Sep 03, 2020 06:30 am ET
InspireMD Announces the European Society of Cardiology 2020 “Best Poster Award” for Updated Data from the PARADIGM-EXTEND Study
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the award for Best ESC Congress Poster for the presentation of...
Aug 31, 2020 05:00 pm ET
(LD Micro) 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 25, 2020 06:30 am ET
InspireMD to Present at the LD Micro 500 Virtual Conference on September 3, 2020
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that Marvin Slosman, President and Chief Executive...
Aug 10, 2020 06:30 am ET
InspireMD Regains Compliance with NYSE AMERICAN Listing Standards
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that as of August 7, 2020, the Company has regained...
Aug 05, 2020 06:41 am ET
InspireMD Announces Second Quarter 2020 Financial Results
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the second...
Jul 29, 2020 04:05 pm ET
UPDATE: InspireMD to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 and Provide Corporate Update
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal second quarter 2020 financial results on...
Jul 28, 2020 08:30 am ET
InspireMD to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 and Provide Corporate Update
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal second quarter 2020 financial results on...
Jul 23, 2020 08:00 am ET
InspireMD Gains Registration Clearance of its CGuard™ Embolic Prevention System (EPS) in Brazil
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced it has obtained registration from the Brazilian registration...
Jun 25, 2020 10:00 am ET
InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease treatment, announced today that early results from the investigator-initiated SIBERIA...
Jun 10, 2020 11:00 am ET
Thinking about buying stock in Nio Inc, Actinium Pharmaceuticals, AMC Entertainment, Oasis Petroleum, or InspireMD?
NEW YORK, June 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, ATNM, AMC, OAS, and NSPR.
Jun 10, 2020 08:00 am ET
InspireMD Announces Publication of 12-Month Results of CGuard™ EPS PARADIGM Trial in EuroIntervention
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease treatment, announced today that 12-month PARADIGM trial results have been published in the...
Jun 08, 2020 08:00 am ET
InspireMD, Inc. Announces Underwriter Exercise of Over-Allotment Option in Full and Closing of $11.5 Million Follow-On Underwritten Public Offering
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today the closing, on June 5, 2020, of its $11.5 million follow-on...
Jun 03, 2020 10:55 am ET
Thinking about buying stock in Zomedica Pharmaceuticals, InspireMD, General Electric, Norwegian Cruise Line, or Evofem Biosciences?
NEW YORK, June 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, NSPR, GE, NCLH, and EVFM.
Jun 03, 2020 07:40 am ET
InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten public offering of 22,222,200 units at...
May 12, 2020 07:00 am ET
InspireMD Announces First Quarter 2020 Financial Results
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the first...
May 05, 2020 08:00 am ET
InspireMD to Report First Quarter 2020 Financial Results and Provide Business Update on Tuesday, May 12
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that management will host a conference call and webcast on Tuesday, May...
Mar 10, 2020 08:00 am ET
InspireMD Announces Fourth Quarter and Year-End 2019 Financial Results
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the fourth...
Mar 03, 2020 08:00 am ET
InspireMD to Report Fourth Quarter 2019 Financial Results and Provide Business Update on Tuesday, March 10
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, March 10,...
Jan 29, 2020 08:00 am ET
InspireMD Announces Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2020
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced that a successful live case featuring CGuard™ EPS was presented at the...
Jan 27, 2020 08:00 am ET
InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmission at LINC, 28th to the 31st January 2020, in Leipzig, Germany
InspireMD, Inc.  (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Carotid Embolic Prevention System (EPS) will be featured in a live...
Jan 06, 2020 08:00 am ET
InspireMD Announces Strong Preliminary Fourth Quarter 2019 Revenue and Reports Inducement Award Under NYSE American Company Guide §711(a)
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced strong preliminary unaudited revenue for the fourth quarter and...
Dec 10, 2019 08:00 am ET
InspireMD Announces Planned Leadership Transition
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced that James Barry, Ph.D. is stepping down as President and Chief...
Nov 26, 2019 08:00 am ET
InspireMD Reports Updated Positive CGuard™ EPS Data Presented at VEITH 2019
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today reported on updated registry study data presented at the 2019 VEITH Symposium,...
Nov 12, 2019 07:00 am ET
InspireMD Announces Third Quarter 2019 Financial Results
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced financial and operating results for the third quarter...
Nov 05, 2019 08:00 am ET
InspireMD to Report Third Quarter 2019 Financial Results and Provide Business Update on Tuesday, November 12
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on...
Sep 19, 2019 09:12 pm ET
InspireMD, Inc. Announces Pricing of $5 Million Underwritten Public Offering
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten public offering of 2,777,777 units at...
Sep 09, 2019 08:05 am ET
InspireMD Provides Business Update
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today provided a business update. Positive CGuard™ EPS Data Presented at the Joint...
Sep 09, 2019 08:00 am ET
InspireMD to Present at the HC Wainwright 21st Annual Global Investment Conference
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced that James Barry, PhD, Chief Executive Officer and Craig Shore, Chief...
Aug 09, 2019 04:30 pm ET
InspireMD Announces Notification of NYSE AMERICAN Listing Deficiency
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it has received a letter from the NYSE American on...
Aug 06, 2019 07:00 am ET
InspireMD Announces Second Quarter 2019 Financial Results
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the second quarter ended June 30, 2019....
Jul 30, 2019 04:05 pm ET
InspireMD to Report Second Quarter 2019 Financial Results and Provide Business Update on Tuesday, August 6
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on...
May 14, 2019 07:00 am ET
InspireMD Announces First Quarter 2019 Financial Results
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the first quarter ending March 31, 2019....
May 07, 2019 08:00 am ET
InspireMD to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 14
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on...
Apr 04, 2019 06:00 am ET
InspireMD, Inc. Announces Pricing of $2.4 Million Public Offering of Common Stock
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the pricing of its previously announced underwritten...
Apr 03, 2019 04:05 pm ET
InspireMD, Inc. Announces Proposed Public Offering of Common Stock
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it intends to offer and sell shares of its common...
Apr 02, 2019 09:31 am ET
Thinking about buying stock in Cronos Group Inc., Facebook Inc., InspireMD Inc., Pulmatrix Inc., or Sangamo Therapeutics?
NEW YORK, April 2, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRON, FB, NSPR, PULM, and SGMO.
Mar 26, 2019 07:00 am ET
InspireMD Announces 1-for-50 Reverse Stock Split
InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its Board of Directors has approved a one-for-fifty reverse...
Mar 22, 2019 06:00 pm ET
InspireMD Provides Amended Disclosure
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today provided an amended disclosure to conform to the Company’s Form...
Feb 19, 2019 07:00 am ET
InspireMD Announces Fourth Quarter 2018 Financial Results
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the fourth quarter ending December 31, 2018....
Feb 07, 2019 08:00 am ET
InspireMD to Report Fourth Quarter and Fiscal 2018 Financial Results and Provide Business Update on Tuesday, February 19
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on...
Jan 24, 2019 08:00 am ET
InspireMD Announces Presentation of Interim Data from Investigator-Initiated Study Comparing CGuard™ EPS with a Conventional Open-Cell Carotid Stent
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the presentation of positive interim results from an...
Jan 23, 2019 08:00 am ET
InspireMD Announces Two Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2019
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that two successful live cases featuring CGuard™ EPS...
Jan 22, 2019 08:00 am ET
InspireMD Announces Results from Initial Clinical Study of The CGuard™ Embolic Prevention System (EPS) with SmartFit™ Technology
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details of a new investigator-initiated trial entitled,...
Jan 18, 2019 09:34 am ET
InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmissions at LINC, 22nd to the 25th January 2019, in Leipzig, Germany
InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Carotid Embolic Prevention System (EPS) will be featured in two live case...
Jan 14, 2019 08:00 am ET
InspireMD Announces the Distribution of CGuard™ Embolic Prevention System in South Africa
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard EPS will be distributed by its...
Jan 11, 2019 04:30 pm ET
InspireMD Receives Noncompliance Notice from NYSE American
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that on January 7, 2019, the Company received a letter...
Dec 18, 2018 08:00 am ET
InspireMD Announces Publication of Meta-Analysis Citing Benefits of Next Generation Mesh-Covered Carotid Stent Systems
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the publication of a meta-analysis of four clinical...
Nov 29, 2018 08:00 am ET
InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITH
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details from several presentations of updated CGuard™...
Nov 28, 2018 08:00 am ET
InspireMD Announces Regulatory and Reimbursement Approval of CGuard™ Embolic Prevention System in Australia
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard™ Embolic Prevention System (EPS)...
Nov 15, 2018 08:00 am ET
Report: Developing Opportunities within InspireMD, Lakeland Industries, ALJ Regional, Alphatec, Jerash Holdings (US), and DocuSign — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of InspireMD, Inc. (NYSE:NSPR), Lakeland Industries, Inc. (NASDAQ:LAKE), ALJ...
Nov 13, 2018 08:00 am ET
InspireMD Announces Upcoming Presentations at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that the Company’s CGuard™ Embolic Prevention System...
Nov 06, 2018 07:00 am ET
InspireMD Announces Third Quarter 2018 Financial Results and Provides Corporate Update
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the third quarter ending September 30, 2018....
Oct 30, 2018 08:00 am ET
InspireMD to Report Third Quarter 2018 Financial Results and Provide Business Update on Tuesday, November 6
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on...
Sep 27, 2018 09:28 am ET
InspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that preliminary cumulative three-year follow-up safety,...
Sep 24, 2018 08:00 am ET
InspireMD Announces Regulatory Approval of CGuard™ Embolic Prevention System in Mexico
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard™ Embolic Prevention System (EPS)...
Sep 17, 2018 08:00 am ET
InspireMD Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet™ Stent Jacket and Related Drug Eluting Technology
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that the United States Patent and Trademark Office...
Sep 04, 2018 07:30 am ET
InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City
via NEWMEDIAWIRE - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced it will be presenting at the H.C....
Aug 06, 2018 04:05 pm ET
InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018
InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the second quarter ending June 30, 2018....
Jul 31, 2018 07:00 am ET
InspireMD Schedules Second Quarter 2018 Earnings Conference Call
InspireMD, Inc. (NYSE: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it will host a conference call on Tuesday, August 7th at...
Jul 23, 2018 08:41 am ET
InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence
InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it has established its first two Centers of Excellence...
Jun 29, 2018 10:24 am ET
InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering
InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an underwritten public offering of 33,333,333 units at a price to the...
Jun 20, 2018 07:20 am ET
InspireMD’s CGuard EPS Featured at the SBHCI Congress in Brazil
InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that CGuard™ EPS was featured at the SBHCI Congress, sponsored by the Brazilian Society of...
Jun 18, 2018 09:42 am ET
InspireMD’s CGuard EPS Prominently Featured at the 10th International Congress of the Polish Society for Vascular Surgery
InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that study results on its CGuard™ EPS were presented at the 10th International Congress of...
Jun 11, 2018 09:53 am ET
InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress
InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ MicroNet™ covered Embolic Prevention System (EPS) was successfully...
May 30, 2018 07:31 am ET
InspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS
InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS),  thrombus management technologies and neurovascular devices, today announced that Professor Piotr Musiałek, from the Department of Cardiac and Vascular Diseases, John...
May 16, 2018 08:12 am ET
InspireMD Receives Regulatory Approval for both CGuard EPS™ and MGuard Prime™ in Ecuador
InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received regulatory approval for the CGuard™ Embolic Prevention System (EPS)...
May 07, 2018 04:05 pm ET
InspireMD Reports 132% Increase in CGuard™ EPS Sales for the First Quarter of 2018
InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced results for the first quarter ending March 31, 2018. First Quarter 2018 highlights:...
May 01, 2018 07:00 am ET
InspireMD Schedules First Quarter 2018 Earnings Conference Call
TEL AVIV, ISRAEL , May 01, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on...
Apr 19, 2018 07:00 am ET
InspireMDs CGuard Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, Poland
TEL AVIV, ISRAEL, April 19, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,  today announced that its CGuard™ Embolic Prevention System will be featured at...
Apr 03, 2018 10:28 am ET
InspireMD Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth; Projects 132% Increase in CGuard EPS Sales for the First Quarter of 2018; Total Quarterly Company Sales to Exceed $1
TEL AVIV, Israel, April 03, 2018 (GLOBE NEWSWIRE) --  InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced preliminary unaudited sales results for the first quarter of 2018....
Mar 28, 2018 06:30 am ET
InspireMD, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock
Tel Aviv, Israel, March 28, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR),  a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an underwritten public offering of 2,857,143...
Mar 27, 2018 04:37 pm ET
InspireMD, Inc. Announces Proposed Public Offering of Common Stock
Tel Aviv, Israel, March 27, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR),  a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it intends to offer and sell, subject to...
Mar 27, 2018 07:00 am ET
InspireMD Receives Regulatory Approval for both CGuard™ EPS and MGuard Prime™ in Peru
Tel Aviv, Israel, March 27, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received regulatory approval for the CGuard™ Embolic...
Mar 05, 2018 08:07 am ET
InspireMD Announces First Patient Treated with CGuard™ EPS in India 
Patient with severe stenosis, calcification and thrombosis successfully treated with CGuard™ EPS
Mar 01, 2018 07:30 am ET
InspireMD Announces Expansion of its Distribution Network
Signs Exclusive Distributors for Greece and Caribbean Countries
Feb 27, 2018 07:00 am ET
InspireMD, Inc. Announces Pricing of Public Offering of Common Stock
TEL AVIV, ISRAEL , Feb. 27, 2018 (GLOBE NEWSWIRE) --  InspireMD, Inc. (NYSE American: NSPR),  a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an underwritten public offering of...
Feb 26, 2018 04:02 pm ET
InspireMD, Inc. Announces Proposed Public Offering of Common Stock
Tel Aviv, Israel, Feb. 26, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR),  a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it intends to offer and sell, subject to...
Feb 20, 2018 09:00 am ET
InspireMD Announces Commercial Launch and First Sales of CGuard™ EPS in India
TEL AVIV, ISRAEL, Feb. 20, 2018 (GLOBE NEWSWIRE) --  InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the commercial launch and first sales of its CGuard™ Embolic...
Feb 14, 2018 07:30 am ET
InspireMD Announces Fourth Quarter and Year-End 2017 Results; CGuard™ EPS Fourth Quarter Sales Increase 211% Versus Same Period Last year
TEL AVIV, Israel, Feb. 14, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced results for the fourth quarter and year-ending December 31,...
Feb 07, 2018 02:36 pm ET
InspireMD Announces 1-for-35 Reverse Stock Split
Tel Aviv, Israel, Feb. 07, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced a 1-for-35 reverse split of its...
Jan 31, 2018 08:31 am ET
InspireMD's CGuard Embolic Prevention System Featured in a Second Live Case Transmission at LINC 2018 by Leading Interventional Cardiologists
TEL AVIV, ISRAEL, Jan. 31, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic Prevention System (EPS) was...
Jan 30, 2018 08:19 am ET
InspireMD’s CGuard™ Embolic Prevention System Featured in Successful Live Case Transmissions at LINC 2018 by Leading Vascular Surgeons
TEL AVIV, ISRAEL, Jan. 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic Prevention System (EPS) was...
Jan 26, 2018 10:11 am ET
InspireMD’s CGuard Embolic Prevention System to be Prominently Featured in Two Live Case Transmissions at LINC 2018
TEL AVIV, ISRAEL, Jan. 26, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc.  (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic Prevention System (EPS) will be featured...
Jan 19, 2018 10:18 am ET
InspireMD Announces Publication of an Independent Imaging Study Highlighting the Advantages of CGuard EPS Compared to Another Next Generation Carotid Stent
TEL AVIV, ISRAEL, Jan. 19, 2018 (GLOBE NEWSWIRE) --  InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the publication of an independent observational study conducted by Tomoyuki...
Jan 10, 2018 07:30 am ET
InspireMD Projects 211% Increase in CGuard(TM) EPS Sales for the Fourth Quarter of 2017
Conference call to be held at 10AM Eastern today to discuss recent developments, preliminary sales results and proposals for upcoming shareholder meeting
Jan 03, 2018 04:05 pm ET
InspireMD Schedules Conference Call to Discuss Recent Developments, Preliminary Sales Results and Proposals for Upcoming Shareholder Meeting
TEL AVIV, ISRAEL, Jan. 03, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on Wednesday,...
Jan 03, 2018 08:56 am ET
InspireMD Announces Regulatory Approval of CGuard EPS in India; Signs Agreement with Leading Indian Medical Device Distributor
TEL AVIV, ISRAEL, Jan. 03, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received regulatory approval for the CGuard™...
Dec 18, 2017 12:05 pm ET
InspireMD’s CGuard™ Embolic Prevention System Once Again Featured in a Successful Live Clinical Case at Leading Industry Conference
Professor Pierfrancesco Veroux treated a patient with carotid artery disease using CGuard™ EPS 
Dec 05, 2017 01:00 pm ET
InspireMD Announces Preliminary 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard™ EPS
No procedure or device related adverse events at 24 months; Results presented at the 2017 VEITHsymposium in New York and ICI Meeting 2017 in Tel Aviv
Nov 29, 2017 07:00 am ET
InspireMD Announces Planned Recapitalization
InspireMD, Inc. (NYSE MKT: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it entered into a securities purchase agreement with an institutional investor for the issuance and sale of 750 shares of InspireMD's Series D Preferred Stock for aggregate gross proceeds of $750,000 as part of a planned recapitalization of the Company.
Nov 07, 2017 04:05 pm ET
InspireMD Announces Third Quarter 2017 Results; CGuard(TM) Revenue Increases 90% Versus Same Period Last Year
InspireMD, Inc. (NYSE American: NSPR), a leader in Embolic Prevention Systems (EPS) / thrombus management technologies and neurovascular devices, today announced preliminary results for the third quarter ending September 30, 2017.
Nov 01, 2017 07:30 am ET
InspireMD Schedules Third Quarter 2017 Earnings Conference Call
InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on Wednesday, November 8th at 8:00 a.m. Eastern Time to discuss the company's financial results for the third quarter ended September 30, 2017, as well as the Company's corporate progress and other meaningful developments.
Oct 25, 2017 07:30 am ET
InspireMD's CGuard(TM) Carotid Embolic Prevention System Featured in Live Case at Cracow Vascular Summit 2017 in Poland
InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) (NYSE American: NSPR) (NYSE American: NSPR.WS), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that Prof. Waclaw Kuczmik, Head of the Vascular Surgery Department of Katowice Clinical Hospital N 7 and his team, performed a live endovascular interventional procedure featuring the CGuard™ EPS at the 4th Edition of the Cracow Vascular Summit (CVS). The case was transmitted real time to the entire congress. Professor Kuczmik is one of the Course Directors of the
Oct 24, 2017 09:47 am ET
New York Stock Exchange Accepts InspireMD's Plan to Regain Compliance
InspireMD, Inc. (NYSE AMER: NSPR) (NYSE AMER: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that the New York Stock Exchange has accepted the Company's plan to regain compliance with the NYSE American's stockholder's equity continued listing standard (Part 10, Section 1003(a)(iii)). As previously disclosed, the NYSE American notified the Company on August 17, 2017, that it had fallen below the NYSE's continued listing standards.
Oct 12, 2017 10:35 am ET
InspireMD Announces Distribution Agreement for MGuard Prime(TM) in Chile
InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with CorpMedical Chile Ltda, a leading medical distributor in Chile, with its headquarters in Santiago de Chile, to distribute the MGuard Prime™ Embolic Protection System (EPS) for the treatment of acute coronary syndromes, namely Acute Myocardial Infarctions (AMI).
Oct 09, 2017 11:06 am ET
InspireMD Announces the Start of Patient Enrollment in an Investigator Initiated Trial of CGuard(TM) EPS in Russia
InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR), a leader in Embolic Prevention Systems (EPS) / thrombus management technologies and neurovascular devices, today announced the start of patient enrollment in an investigator initiated trial in Russia, entitled: Independent Randomized Trial in Carotid Artery Revascularization Comparing the Stent (Acculink™) Versus CGuard™EPS. The objective of the trial is to assess the neuro protection and clinical superiority of the minimally invasive interventional procedure with the CGuard™ EPS versus Abbott's RX ACCULINK®
Oct 04, 2017 09:02 am ET
InspireMD Postpones Special Meeting of Stockholders to October 27, 2017
InspireMD, Inc. (NYSE MKT: NSPR) (NYSE American: NSPR) (NYSE MKT: NSPR.WS) (NYSE American: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has postponed its Special Meeting of Stockholders that was to have taken place originally on October 3, 2017. The new date for the Special Meeting is October 27, 2017 at 11:30 a.m. Eastern time and it will take place at the offices of Haynes and Boone, LLP, located at 30 Rockefeller Plaza, 26th Floor, New York, New York 10112. The
Sep 21, 2017 07:30 am ET
InspireMD Announces Distribution Agreement for CGuard(TM) EPS in Portugal
InspireMD, Inc. (NYSE MKT: NSPR) (NYSE American: NSPR) (NYSE MKT: NSPR.WS) (NYSE American: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with Medicinália Cormédica MC Medical Lda, a leading medical distributor in Portugal, to distribute CGuard™ EPS (Embolic Prevention System). Medicinália Cormédica MC Medical Lda is a subsidiary of WerfenLife Company, one of Europe's largest distributors of medical products.
Sep 06, 2017 01:10 pm ET
InspireMD to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City
InspireMD, Inc. (NYSE American: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it will present at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City.
Aug 25, 2017 09:00 am ET
InspireMD Announces Distribution Agreement for CGuard(TM) EPS in Switzerland
InspireMD, Inc. (NYSE AMER: NSPR) (NYSE AMER: NSPR.WS) (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with 1a medical ag, a leading medical distributor in Switzerland, to distribute CGuard™ EPS (Embolic Prevention System).
Aug 22, 2017 08:05 am ET
InspireMD Shares CGuard(TM) EPS Video Testimonials from European Key Opinion Leaders
InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has posted video testimonials about its CGuard™ Embolic Prevention System from several European key opinion leaders on its website: http://www.inspiremd.com/en/kol-testimonials/
Aug 22, 2017 08:00 am ET
InspireMD Announces Notification of NYSE AMERICAN Listing Deficiency and Expectation to Regain Compliance
InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it received a letter from the NYSE American on August 17, 2017 indicating that InspireMD does not meet a certain NYSE American LLC (the "NYSE American") continued listing standard as set forth in Part 10, Section 1003(a)(iii) of the Company Guide of the NYSE American, due to the fact the Company had reported stockholders' equity of less than $6 million as of June 30, 2017 and had net
Aug 08, 2017 04:05 pm ET
InspireMD Reports Double Digit Sequential and Year-Over-Year Revenue Growth for the Second Quarter of 2017
InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today provided a business update, including the successful transition of all territories previously covered by the Company's former European distributor to a local network of regional distributors. The Company also reported financial and operating results for the second quarter ended June 30, 2017.
Aug 07, 2017 07:54 am ET
InspireMD Announces Publication of an Independent Clinical Review Authored by Leading U.S. and European Physicians Supporting Safety Advantages of Mesh-Covered Carotid Stents
InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the publication of the independent study entitled, "One swallow does not a summer make but many swallows do: accumulating clinical evidence for nearly-eliminated peri-procedural and 30-day complications with mesh-covered stents, transforms the carotid revascularization field," in the Advances in Interventional Cardiology Journal 2017. The
Aug 03, 2017 07:30 am ET
InspireMD's CGuard Carotid Embolic Prevention System Featured at the SOLACI CACI Congress of Cardiology 2017 in Buenos Aires
InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that an endovascular interventional procedure featuring the CGuard™ EPS performed by the team of Dr. Anibal Damonte, Interventional Cardiologist, Director of Interventional Cardiology at the Cardiovascular Institute of Rosario, and Vice President of the Argentine College of Interventional Cardiology, as well as Dr. Maximiliano Rossi, Interventional Cardiologist at the Cardiovascular
Aug 02, 2017 07:30 am ET
InspireMD Schedules Second Quarter 2017 Earnings Conference Call
InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on Wednesday, August 9th at 8:00 a.m. Eastern Time to discuss the company's financial results for the second quarter ended June 30, 2017, as well as the Company's corporate progress and other meaningful developments.
Jun 13, 2017 07:00 am ET
InspireMD Announces Completion of Transition from Exclusive European Distributor to InspireMD Managed Local Distribution Network
InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed distribution agreements for CGuard™ EPS with Comesa GmbH, as well as "be medical," who are among the leading medical distributors in Austria and Belgium, respectively. Consequently, all territories previously covered by Penumbra, InspireMD's former European distributor, have now been transferred to local distributors.
Jun 09, 2017 07:00 am ET
InspireMD to Present at the 2017 Marcum Microcap Conference
InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it will be presenting at the 2017 Marcum MicroCap Conference on Friday, June 16th at 10:30 AM EST. James Barry, PhD, Chief Executive Officer of InspireMD will be presenting and meeting with investors.
Jun 08, 2017 07:00 am ET
InspireMD Announces Distribution Agreement for CGuard EPS in Taiwan
InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with LORION Enterprises Inc., a leading medical distributor in Taiwan, to distribute CGuard™ EPS (Embolic Prevention System).
Jun 07, 2017 07:00 am ET
InspireMD Announces the Publication of an Investigator Initiated Clinical Registry Reaffirming MGuard(TM) Prime as a Highly Effective Tool to Prevent Heart Damage in Coronary Artery Blockages with Hig
InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the publication of an independent clinical study entitled, "Long term Outcomes of MGuard™ Stent Deployment in Saphenous Vein Grafts and Native Coronary Arteries: A Single Center Experience," in the Israel Medical Association Journal.
Jun 05, 2017 08:15 am ET
InspireMD Announces Distribution Agreement for CGuard(TM) EPS in Poland
InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with Arteriae Sp. z o.o. sp.k, a leading medical distributor in Poland, to distribute CGuard™ EPS (Embolic Prevention System).

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.